Tatva Chintan: Board Approves FY26 Results, ₹2 Dividend
The Board of Directors of Tatva Chintan Pharma Chem Ltd approved the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹2 (20%) per equity share of ₹10 each for FY26, subject to shareholder approval. The board also approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.
Key Highlights
- Audited financial results for FY26 approved (standalone and consolidated).
- Final dividend of ₹2 (20%) per share recommended for FY26.
- Zarna Thakar & Associates appointed as Cost Auditor for FY27.
- RSM Astute Consultech Private Limited appointed as Internal Auditor for FY27.
Price Impact
More from TATVA
More in Board Meeting
Sambhv Steel Tubes Board Meeting on July 15, 2026 to Consider Fund Raising
Vineet Laboratories Board Meeting on July 15, 2026 for Audited Results
LTM (ex-LTIMindtree) Q1 strong: consol PAT +17% YoY to ₹1,469 Cr, revenue +18%, margins expand